Veracyte, Inc. (VCYT) Stock Score, Valuation & Financial Research
Veracyte, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 40/100.
Quick answer for VCYT
Veracyte, Inc. currently has a Wall Street Score of 40/100. The stored market price is $40.14. Its financial score is 39/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Veracyte, Inc. does
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT financial snapshot
- Wall Street Score:
- 40/100
- Current price:
- $40.14
- Market capitalization:
- $3.20B
- Revenue:
- $541.7M
- Net income:
- $88.0M
- Free cash flow:
- $126.6M
- Cash:
- $263.1M
- Total debt:
- $39.3M
- EPS:
- 0.84
- P/E ratio:
- 47.8x
- Financial score:
- 39/100
- Valuation score:
- 0/100
- Revenue score:
- 30/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $126.6M, showing positive cash generation.
- The balance sheet shows $263.1M of cash versus $39.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research VCYT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.